Indianapolis, Indiana Saturday, January 3, 2026, 10:00 Hrs [IST] ...
Elanco Receives USDA Approval for Befrena (tirnovetmab), a New Anti-IL31 Monoclonal Antibody Injection Targeting Canine Allergic and Atopic Dermatitis. News release. Elanco Animal Health. December 31, ...
SaveHealth reports on eczema medications, detailing various options from topical treatments to advanced therapies for ...
Researchers have found in a new real-world study that dupilumab was an effective and safe therapeutic option for head and ...
Elanco Animal Health Incorporated (NYSE: ELAN) today announced its latest entry into the rapidly growing canine dermatology ...
And the most recent article came out of JAMA in 2024, and they found that for every 1 g increase in urinary sodium, you ...
Johnson & Johnson (NYSE:JNJ) is included among the 14 Best Pharma Dividend Stocks to Buy in 2026. On December 26, Johnson & ...
Johnson & Johnson has discontinued a phase 2 trial of one of its pipeline candidates for atopic dermatitis (AD), after it ...
A new study published in the journal of Inflammopharmacology showed that in individuals with moderate-to-severe atopic ...
Stocktwits on MSN
Johnson & Johnson terminates experimental eczema drug study after it fails to show benefit
The drug JNJ-5939 was being evaluated in the treatment of moderate to severe atopic dermatitis in a mid-stage study. ・JNJ, ...
The company said the results of a planned interim analysis met prespecified criteria for early termination of the study. "They did not meet the high-bar efficacy we established for advancing our ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback